Skip to main content
. 2008 Jul 23;112(8):3383–3390. doi: 10.1182/blood-2007-10-115600

Table 2.

Main clinical features and treatment outcome of sAPL patients

Patient no. Age (y) at time of APL diagnosis Sex APL characteristics
Therapy of APL Outcome
WBC, ×109/L PLT, ×109/L DIC, Yes/No
UPN 1 60 F 5.5 25 Yes PETHEMA APL 2005 Died at 7 months due to cerebral hemorrhage
UPN 2 59 F 8.9 74 Yes GIMEMA AIDA protocol CCR 21 mo
UPN 3 58 F 0.5 37 No PETHEMA APL 2005 CCR 16 mo
UPN 4 36 F 0.8 74 No GIMEMA AIDA protocol CCR 16 mo
UPN 5 26 F 1.1 30 Yes GIMEMA AIDA protocol CCR 24 mo
UPN 6 59 F 1.1 58 Yes GIMEMA AIDA protocol CCR 19 mo
UPN 7 28 M 0.7 5 No UK MRC protocol Relapse at 28 mo
UPN 8 61 M 3.3 31 No PETHEMA APL 2005 CCR 4 mo
UPN 9 45 M 13 12 No GIMEMA AIDA protocol CCR 4 mo
UPN 10 27 M 33.7 11 Yes GIMEMA AIDA protocol CCR 10 mo
UPN 11 45 M 0.6 66 No GIMEMA AIDA protocol CCR 10 mo
UPN 12 67 M 1.1 9 No PETHEMA APL 2005 CCR 9 mo
UPN 13 55 F 8.9 13 Yes NA Died 3 h after APL diagnosis
UPN 14 45 F 72.2 40 Yes PETHEMA APL 2005 CCR 1 mo

DIC indicates disseminated intravascular coagulation; CCR, continuous complete remission; and NA, not applicable.